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The adjective “translational” stems fromAncient Latin “trans-
latio” (transfero, carry over). Translational research is the
branch of scientific research aimed at transferring discoveries
obtained in basic research investigations to the clinical con-
text. Accordingly, in the field of biomedical sciences the con-
cept of translational research relates to the transfer of scien-
tific knowledge into practical clinical applications in order to
improve the management and treatment of human diseases.
Medicine in general is particularly fascinated by the
translational concept, probably for its peculiar applied scopes,
and cardiology is not an exception. In this regard, the Inter-
national Society for Cardiovascular Translational Research
(http://www.isctr.org/) was founded in 2007 with the objec-
tive to coordinate and guide basic and clinical researchers,
regulatory authorities, and the medical industry to improve
the process of transferring new scientific evidence into clini-
cal applications, promote translational research and divulgate
new scientific results to the scientific community, and develop
guidelines for conducting translational research studies. In
addition, the ISCTR and the American College of Cardiology
(ACC) collaborative efforts began in 2010 involving education
on translational science pathways.
The reason behind the interest for translation research in
the cardiovascular field is obvious. Although huge advances
in the treatment of cardiovascular diseases have been made
during the last decades, the morbidity and mortality associ-
ated with heart diseases are still too high [1]. In particular,
the incidence of heart failure continues to increase with a
progressively higher overload for national health systems
and health care providers involved in the management of
this chronic and highly disabling disease. For all these
reasons, it is crucial to develop new therapeutic strategies
for the prevention and treatment of cardiac diseases, with a
particular focus on heart failure. However, the only way to
be successful in this difficult task is to implement the efforts
devoted to translational research.
One important goal of cardiovascular translational
research is the discovery of new biomarkers that could
be useful for the diagnosis, prognostic stratification, and
therapeutic management of specific cardiac diseases [2]. This
can be achieved by testing whether factors, which were
previously found to be associatedwith specific cardiovascular
disease models in experimental studies, are indeed useful
for the clinical management of patients affected by these
illnesses. These biomarkers could be circulating humoral
factors or specific cellular subtypes, or preclinical markers
of organ damage. For example, it is now well established
that a reduction of flow-mediated artery dilation in human
subjects is a preclinical sign of endothelial dysfunction and an
independent predictor of adverse cardiovascular events [3].
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Another important interest of translational research is the
elucidation of the genetic basis of cardiovascular diseases. In
fact, the clarification of the genetic predisposition to cardio-
vascular illnesses can help to identify those subjects who need
a different clinical management. Genome-wide association
studies are continuously providing new insights into the
gene variants associated with cardiovascular sicknesses [4].
However, case-cohort studies or longitudinal investigations
are also brilliantly identifying new polymorphisms linked
to an increased incidence of cardiovascular diseases or to a
worse prognosis. For example, recent studies demonstrated
that T2238C atrial natriuretic peptide gene variant is inde-
pendently associated with an increased incidence of adverse
cardiovascular events [5].
A fundamental field in cardiovascular research is also
represented by the study of cardioprotection [6]. In fact, the
discovery of new therapies reducing the amount of myocar-
dial death during an acute myocardial infarction would help
to significantly reduce the incidence of subsequent cardiac
dysfunction and heart failure. This would be possible only if
themechanisms regulating cardiomyocyte survival and death
during myocardial ischemia are elucidated so that appropri-
ate therapeutic targets can be identified. Unfortunately, in the
last decades only fewof the therapeutic interventions effective
in the reduction of myocardial infarction and cardiac remod-
eling in animal models of ischemia, ischemia/reperfusion,
and chronic myocardial infarction resulted to be effective
also in patients experiencing a real heart attack. This may
be due to the fact that the animal models of myocardial
ischemia and infarction currently employed in basic exper-
imental studies do not accurately mimic the pathophysiology
of a human myocardial infarction [7]. Future efforts of
researchers working on cardioprotection should be devoted
to the development of more relevant models of cardiac
diseases.
Finally, a fascinating and promising field of translational
research is represented by cardiac regeneration. The pos-
sibility for physicians to repair a failing heart with stem
cells or applied tissue-engineered myocardial patches still
represents a new frontier for the treatment of heart failure
[8]. Unfortunately, as in the field of cardioprotection, most
of the attempts to effectively translate the highly promising
experimental results obtained in this field into the clinical
setting highlighted mixed results with benefits ranging from
absent to transient or, at most, marginal [9, 10]. A part of
the delay in the therapeutic advancement in the field of stem
cells and cardiac regeneration is caused by the fact that little
is still known about the mechanisms to increase stem cell
survival after in vivo transplantation and to efficiently induce
its transdifferentiation into mature cardiomyocytes. These
mechanisms need to be urgently elucidated in future inves-
tigations. In addition, the standardization of the procedures
for isolation, purification, manipulation, and transplantation
of human stem cells used for therapeutic purposes needs to be
implemented, despite the fact that the standards of safety and
quality for stem cell therapeutic uses are currently defined
in the Good Manufacturing Practice (GMP) guidelines (see
Eudralex EU guidelines for GoodManufacturing Practice for
Medicinal Products for Human and Veterinary Use) [11, 12].
Nonetheless, full compliance with GMP is a mandatory
aspect of stem cell-tissue engineering and manufacturing.
The improvement of translational research, however, can-
not represent alone the solution for developing new strategies
for the cure of cardiovascular diseases. Together with trans-
lational research, it would be highly important to implement
also clinical and outcome research. These scientific research
branches aim to further expand the current knowledge
of the prevalence, incidence, impact, and management of
cardiovascular abnormal conditions in selected or real-world
patients.This would help to identify shortfalls in practice and
to develop strategies to improve care. In particular, outcome
research is planned to continuously provide new insights into
the therapeutic interventions working best for specific types
of patients and under specific circumstances.
Given these premises, this special issue aimed at inte-
grating expertise from different disciplines toward the same
objective: a deeper understanding of the mechanisms under-
lying cardiovascular diseases as well as the development of
new therapeutic strategies to prevent or treat cardiovascular
diseases. In our opinion the result was notable. Among the
accepted manuscripts, some studies developed new methods
enhancing the cardiovascular transdifferentiation of stem
cells or standardized the procedures for the isolation of bone
marrow-derived cellular subtypes for the treatment of refrac-
tory ischemia. Other manuscripts dealt with the molecular
mechanisms underlying ischemia/reperfusion damage or
heart failure with preserved ejection fraction.The biomarkers
associated with resistant hypertension or aortic aneurism
rupture were also studied. In addition, some epidemiologic
studies provided new insights into the factors associated
with coronary artery disease or with a worse cardiovascular
outcome. Finally, the genetic basis of metabolically unhealthy
obesity was also investigated.
The editors really hope that the scientific contributions
accepted for this special issue may contribute in some extent
to the advance of the current knowledge of the pathophysiol-
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